Celgene to File Luspatercept BLA With FDA in April
26 Febrero 2019 - 7:54AM
Noticias Dow Jones
By Colin Kellaher
Celgene Corp. (CELG) on Tuesday said it expects to file a
biologics-license application with the U.S. Food and Drug
Administration in April for luspatercept, which it is jointly
developing with fellow biopharmaceutical company Acceleron Pharma
Inc. (XLRN).
The BLA will cover adults with anemia related to very low to
intermediate myelodysplastic syndromes with ring sideroblasts who
require red blood cell transfusions, and adults with anemia related
to beta-thalassemia who require regular red blood cell
transfusions.
Celgene, based in Summit, N.J., and Acceleron, based in
Cambridge, Mass., in December said a phase 3 study showed
luspatercept resulted in statistically significant increased red
blood cell transfusion independence compared to placebo, adding
that they planned to make regulatory submissions in the U.S. and
Europe in the first half of 2019.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 26, 2019 08:39 ET (13:39 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about Acceleron Pharma Inc (NASDAQ): 0 recent articles
Más de Acceleron Pharma Inc. Artículos de Noticias